Yield-Adjusted Batch Size
Yield-Adjusted Batch Size is the planned batch size, re-scaled before dispense begins, when the full nominal size on the MMR cannot or should not be made — input shortage, vessel-capacity ceiling, a sub-potent active that would drive counter-balance negative, equipment downtime that forces a smaller run, or a deliberate scale-down for a clinical / stability / validation lot. It is not the actual yield (that's measured at the end), not the theoretical yield (that's the nominal MMR target), and not a yield-loss cover (that's overage). It is the new top-of-batch denominator that every other adjusted target then derives from: every active is scaled to the new size, every excipient is scaled to the new size, the counter-balance contract holds against the scaled diluent target, the IPC sample mass is re-checked against the validated range, the fill-volume target is re-confirmed, and the mixing-vessel fill is re-verified against the validated tip-speed window. The re-scaled MMR is what gets snapshotted into work_orders.mmr_snapshot, what the dispense kiosk dispenses against, what the BMR renders, and what yield reconciliation closes against. Get the order of operations wrong (e.g. recalculate active for PF / LOD / SBF first, then scale, instead of scaling first then recalculating) and the counter-balance figure is wrong by the scale factor — the operator weighs the right active but the wrong diluent and total batch mass drifts. Skip the validated-window check and a 30% scale-down can put the mixing-vessel fill below the impeller, the impeller stops imparting shear, the granulation fails, and the batch is a deviation before dispense even finishes. The discipline this page covers: when scale-down is allowed (validated range explicit on MMR), when it is forbidden (outside validated range = process change requiring re-qualification), the math (scale factor = adjusted size ÷ nominal size, applied to every formula row before any per-lot correction), the e-signature contract (a yield-adjusted release is a deliberate decision documented under 21 CFR 211.100 / 211.186 — not a unilateral kiosk override), the regulatory anchors (Annex 15 process validation, ICH Q8(R2) design space, 21 CFR 211.110 in-process controls, 211.165(d) acceptance criteria, 211.188(b)(11) batch records, 111.260 supplements, EU GMP Ch.5 §5.40–§5.43), the failure modes (scale before recalculate / scale outside validated range / scale without IPC re-check / shared-vessel scale-up violation / partial-scale e-sig missed), the KPI suite, and how V5 Ultimate runs scale-adjustment as a first-class WO-release decision with two-person e-sig, design-space gating, and automatic re-derivation of every downstream target.
01What yield-adjusted batch size actually is
Yield-Adjusted Batch Size is the planned batch size, re-scaled before any dispense weighing begins, when the full nominal size on the MMR cannot or should not be made for this run. Five legitimate triggers: (1) input shortage — only enough of a critical raw material on hand for a 70% run; (2) vessel-capacity ceiling — the requested batch would exceed the mixer's working volume because a new excipient is lower density; (3) sub-potent active that, after PF + LOD + SBF recalculation, would push the counter-balance excipient negative at full size but lands positive at 60% size; (4) equipment downtime — one of two parallel mixers is offline so the batch is halved to fit the remaining equipment's schedule; (5) deliberate scale-down for a clinical, stability, or validation lot.
It is not the actual yield (that's measured at the end), not the theoretical yield (that's the nominal MMR target), and not a yield-loss cover (that's overage). It is the new top-of-batch denominator that every other adjusted target then derives from. The scale factor = adjusted size ÷ nominal size, and every formula row — active, excipient, counter-balance, processing aid — is multiplied by the scale factor before any per-lot correction (PF, LOD, SBF) is applied.
02When scale-adjustment is allowed (and when it isn't)
Scale-adjustment is allowed only inside the validated batch-size range declared on the MMR. That range is the product of process-validation work under 21 CFR 211.100 + Annex 15 — typically expressed as a min/max kg (or L) pair and sometimes with discrete validated sizes (e.g. 100 kg, 250 kg, 500 kg only). Inside the range, scale-adjustment is a routine release decision with a two-person e-sig. Outside the range — even by 1% — it is a process change requiring change control, re-qualification, and (depending on regime) regulatory notification.
| Scale request | Validated range | Inside or outside | Decision path |
|---|---|---|---|
| Run 180 kg of a product with validated range 150–250 kg | 150–250 kg | Inside | Routine YA release with two-person e-sig under §211.100 |
| Run 120 kg of a product with validated range 150–250 kg | 150–250 kg | Outside (low) | Change control + re-qualification at the new size; or split into 75 kg lots if 75 kg is validated |
| Run 270 kg of a product with validated range 150–250 kg | 150–250 kg | Outside (high) | Change control + re-qualification; never run as a stretched batch silently |
| Run 100 kg of a product validated only at 100/250/500 kg discrete points | 100 / 250 / 500 kg | Inside (discrete) | Routine YA release |
| Run 175 kg of a product validated only at 100/250/500 kg discrete points | 100 / 250 / 500 kg | Outside (between discrete) | Change control + re-qualification; or split into validated discrete sizes |
03The math, with worked examples
Scale factor = adjusted batch size ÷ nominal batch size. Every formula row is multiplied by the scale factor before any per-lot correction is applied. The order of operations matters: scale first, then PF / LOD / SBF / counter-balance, then dispense.
| Step | Nominal MMR (250 kg) | Scaled to 180 kg (sf=0.720) | After PF correction (lot PF=1.029) | What operator weighs |
|---|---|---|---|---|
| Active A (5.000 kg/batch) | 5.000 kg | 3.600 kg | 3.704 kg | 3.704 kg |
| Active B (2.500 kg/batch) | 2.500 kg | 1.800 kg | 1.800 kg (PF=1.000) | 1.800 kg |
| Binder PVP K30 (3.750 kg) | 3.750 kg | 2.700 kg | 2.700 kg (not subject to PF) | 2.700 kg |
| Disintegrant croscarmellose (5.000 kg) | 5.000 kg | 3.600 kg | 3.600 kg | 3.600 kg |
| Counter-balance lactose (230.000 kg) | 230.000 kg | 165.600 kg | 165.496 kg (absorbs +0.104 kg active-A delta) | 165.496 kg |
| Total batch mass | 250.000 kg | 180.000 kg | 180.000 kg (unchanged) | 180.000 kg dispensed |
04The release contract: who authorises a yield-adjusted batch
A yield-adjusted release is a deliberate decision, not a kiosk override. It is documented in the BMR with: the trigger (input shortage / equipment / vessel ceiling / sub-potent active / planned scale-down), the requested size, the scale factor, the validated range from the MMR, confirmation the requested size is inside the range, the scaled formula table, the IPC sample-mass re-check (still inside the validated IPC range), the fill-volume re-check, the mixing-vessel fill re-check, and a two-person e-signature under 21 CFR 11.50 + 11.70.
- Preparer (production supervisor or planner) — proposes the scale, documents the trigger, attaches the scaled formula table.
- Reviewer (independent QA or designated production reviewer) — confirms validated-range coverage, IPC / fill-volume / vessel-fill re-checks are inside their respective validated windows, e-signs the release.
- Both signatures are Part 11 e-sigs (link to user, link to record, link to timestamp, link to meaning — 'authorised yield-adjusted release at 180 kg').
- The scaled MMR is snapshotted into work_orders.mmr_snapshot at release; dispense, IPC, fill, and reconciliation all run against the snapshot, never against live MMR.
05Regulatory overlay across regimes
| Clause | Regime | What it requires |
|---|---|---|
| ICH Q8(R2) §2.4 + §2.5 | Global | Design space — the validated batch-size range is part of the design space; operating outside requires re-qualification. |
| ICH Q9(R1) | Global | Quality Risk Management — scale-adjustment is a risk-bearing decision that requires documented risk assessment when at the edge of the validated range. |
| ICH Q10 §3.2.3 | Global | Pharmaceutical Quality System — change management process applies whenever the scale falls outside the validated range. |
| ICH Q11 §3 | Global | Drug substance development — scale-up and scale-down behaviour must be characterised. |
| 21 CFR 211.100 | US human drugs | Written procedures for production; any deviation including a non-validated scale must be recorded and justified. |
| 21 CFR 211.110 | US human drugs | In-process controls — IPC sample mass and timing must re-check against validated ranges at the new scale. |
| 21 CFR 211.165(d) | US human drugs | Acceptance criteria for sampling and testing — IPC acceptance ranges hold at all validated scales. |
| 21 CFR 211.186 | US human drugs | MMR includes the validated batch-size range and the procedure for scale-adjustment within it. |
| 21 CFR 211.188(b)(11) | US human drugs | Batch record captures the scaled targets and the e-sig that authorised the scale. |
| 21 CFR 111.260 | US supplements | Batch records include the unique identifier, weight, and the yield calculation — against the scaled theoretical, not nominal. |
| EU GMP Ch.5 §5.40–§5.43 | EU medicinal products | Yield reconciliation against the planned (scaled) figure; deviations investigated. |
| EU GMP Annex 15 §6 | EU medicinal products | Process validation — the validated range is the boundary of routine scale-adjustment. |
| PIC/S PE 009 Part I Ch.5 | Global PIC/S | Mirrors EU GMP Ch.5 for non-EU PIC/S Member States. |
| FDA Process Validation Guidance 2024 rev | US human drugs | Stage 3 continued process verification — scale-adjustment data feeds into ongoing process verification. |
06Six quiet failure modes that produce mis-scaled batches
- Recalculate first, then scale — operator (or upstream system) applies PF / LOD / SBF to the nominal MMR figures, then scales the recalculated numbers; counter-balance derivation breaks; total batch mass drifts; multi-batch accumulation produces a systematic under- or over-dose pattern that surfaces months later in yield reconciliation trending.
- Scale outside validated range without change control — input shortage forces a run at 120 kg against a 150–250 kg validated range; production decides 'we'll just adjust the time / speed / fill' without re-qualification; the resulting batch has unvalidated process parameters, and even if CQAs pass, the batch is a deviation under §211.100.
- Scale without IPC re-check — IPC sample mass is typically 50–250 g taken at a specific point in the process; at a different batch size, the same absolute sample mass represents a different fraction of the batch, which can fall outside the validated IPC range. Recurring 483 area when IPC procedures don't carry the scale-sensitivity check.
- Shared-vessel scale-up violation — plant decides to scale up from 180 kg to 220 kg to use spare capacity but the mixer's working-volume ceiling is 200 kg at the formulation's density; mixing is incomplete; granulation fails.
- Partial-scale e-sig missed — production supervisor changes scale at WO release but the reviewer e-sig is captured against the original (nominal) scaled formula table; the BMR carries a mismatch between authorising e-sig and what was actually dispensed.
- Scale-adjustment used to mask yield-loss trend — repeated 'scale-adjustment for input shortage' across batches actually masks a yield-loss trend in upstream operations; the unscaled batches would show the yield-loss visibly, the scaled batches close on the new (lower) theoretical, and the trend stays invisible until quarterly yield-reconciliation review surfaces it.
07The KPI suite that proves the contract holds
- Yield-adjusted batch coverage % — fraction of WO releases at non-nominal scale that ran through the full YA release contract (two-person e-sig + validated-range confirmation + IPC re-check) (target 100%).
- In-validated-range scale % — fraction of YA batches whose requested size fell inside the validated range (target 100%; outside-range cases must run through change control, not YA release).
- Scale-first compliance % — fraction of WO snapshots whose scaling was applied before per-lot recalculation (target 100%; checked by comparing snapshot order in the audit trail).
- IPC re-check compliance % — fraction of YA batches where the IPC sample-mass re-check is captured in the BMR (target 100%).
- Fill-volume re-check compliance % — fraction of YA liquids batches where the fill-volume re-check is captured in the BMR (target 100%).
- Vessel-fill re-check compliance % — fraction of YA batches where the mixing-vessel fill at the scaled size has been confirmed against the validated tip-speed window (target 100%).
- YA two-person e-sig compliance % — fraction of YA WO releases with both preparer + reviewer e-sigs under Part 11 §11.50 + §11.70 (target 100%).
08How V5 Ultimate runs yield-adjusted release
- MMR schema: validated_batch_size_min, validated_batch_size_max, and validated_discrete_sizes[] are first-class fields on the master record; the MMR-approval e-sig flow requires these to be populated.
- WO planning: the planner can request any size, and V5 immediately surfaces validated-range coverage — green if inside the range / inside a discrete validated size; amber with a 'change control required' callout if outside.
- WO release gate: a non-nominal scale requires the YA release contract — trigger reason picker (input shortage / equipment / vessel ceiling / sub-potent active / planned scale-down / other-with-justification), scaled-formula table preview, IPC re-check, fill-volume re-check, vessel-fill re-check, and two Part 11 e-sigs (preparer + reviewer, two distinct users).
- Snapshot order enforcement: scaled MMR is computed first and locked into work_orders.mmr_snapshot before any per-lot correction is applied; the dispense engine runs PF / LOD / SBF / counter-balance against the snapshot, never against live MMR.
- Kiosk hard-block: kiosk operators cannot scale unilaterally — there is no scale field on the dispense screen. Scale is a release-time decision, full stop.
- Counter-balance integration: counter-balance derivation runs against the scaled formula, not the nominal formula; the negative-counter-balance check fires against the scaled figure, not the nominal one.
- IPC integration: in-process tests run with sample-mass + timing recomputed for the scaled size; IPC acceptance criteria hold; out-of-range sample mass blocks the IPC.
- BMR rendering: the BMR header shows nominal MMR size, requested scaled size, scale factor, trigger reason, validated range, and the two YA e-sigs alongside the standard MMR-snapshot e-sig.
- Yield reconciliation: closes against the scaled theoretical, not the nominal theoretical; trending separates scaled vs nominal yield trajectories so an upstream yield-loss trend masked by scaling becomes visible quickly.
- Quarterly review: ICH Q10 §3.2.5 PQS management review surfaces the YA-batch report — total count, distribution across triggers, validated-range coverage, and trending — so management sees scale-adjustment patterns and either re-qualifies a wider range or addresses the upstream supply trigger.
Frequently asked questions
Q.Is yield-adjusted release the same as a partial dispense?+
No. Partial dispense is one row of a planned batch weighed in two or more sub-dispenses (e.g. operator weighs out 50 kg as 25 + 25 because the scale max is 30 kg). The planned batch size hasn't changed. Yield-adjusted release changes the planned batch size before dispense starts; every row is scaled, the snapshot is re-derived, and a two-person e-sig authorises the new plan.
Q.What if the validated range is 'TBD' on a legacy MMR?+
Then YA release is not allowed for that product until the MMR is updated with a validated range. The interim is to make the nominal MMR size the only allowed size, and surface a remediation task to the QA team to backfill the range from PPQ / commercial-batch data.
Q.Can a YA release happen mid-batch?+
No. YA release is a pre-dispense decision. Once dispense has started, any change in plan is a deviation, not a YA release. Mid-batch corrections live in in-process reconciliation and (for material additions) in the change-control / deviation pathway.
Q.What about supplements under 21 CFR 111?+
Same logic. 21 CFR 111.260(g) requires the batch record to include 'a statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing.' The 'theoretical' is the scaled theoretical, not the nominal MMR figure. The YA release decision itself is documented under 21 CFR 111.260 + 111.103 (written procedures and deviation handling).
Q.Does scale-down outside the validated range ever happen without change control?+
Only in the rare case where the regulator has accepted a process-design rationale that explicitly covers the scaled mode — e.g. a clinical-supply manufacture where the scaled lot is part of an IND/IMPD-covered protocol. Even then, the protocol is the change-control evidence. There is no 'one-off small lot' loophole in commercial manufacture.
Q.What about continuous manufacturing under ICH Q13?+
Q13 changes the framing: the 'batch' is defined by a run-time window or a mass quantity, and adjustment is in run-length or mass, not batch-count. The principle holds — adjustments must stay inside the validated window of operating parameters — but the implementation is in process-control system parameters rather than a discrete YA release event.
Q.Does V5 capture the trigger reason as structured data or free text?+
Structured. The picker has fixed values (input shortage / equipment / vessel ceiling / sub-potent active / planned scale-down / other-with-mandatory-justification). Structured triggers let the quarterly review surface patterns — e.g. 'input shortage drove 22% of YA releases this quarter, all on the same API supplier; the YA mechanism is masking a procurement problem that needs an upstream fix.'
Primary sources
- ICH Q8(R2) — Pharmaceutical Development (design space + validated range)
- ICH Q9(R1) — Quality Risk Management
- ICH Q10 — Pharmaceutical Quality System
- ICH Q11 — Development and Manufacture of Drug Substances
- 21 CFR 211.100 — Written procedures; deviations
- 21 CFR 211.110 — Sampling and testing of in-process materials and drug products
- 21 CFR 211.165(d) — Testing and release for distribution
- 21 CFR 211.186 — Master production and control records
- 21 CFR 211.188(b)(11) — Batch records: weights of each component
- 21 CFR 111.260 — Batch records for supplements
- EU GMP Part I Chapter 5 §5.40–§5.43 — Production: yield and reconciliation
- EU GMP Annex 15 §6 — Process validation (validated range)
- FDA Guidance — Process Validation: General Principles and Practices (2011, rev. 2024)
- PIC/S PE 009 Part I Ch.5 — Production (yield + reconciliation)
Further reading
- Assay-Adjusted ChargePer-lot weigh-out recalculation that runs after batch size is scaled, never before.
- Potency FactorThe lot attribute applied after scaling, not against the nominal MMR.
- Counter-Balance ExcipientThe diluent that re-derives against the scaled formula, not the nominal one.
- In-process reconciliationMid-batch closure that runs against the scaled, not nominal, theoretical.
- Yield reconciliationEnd-of-batch closure that closes against scaled theoretical, with deviation if outside design space.
- MMRThe master record that declares the validated batch-size range scaling is allowed against.
- BMRCaptures the scale factor, the scaled targets, and the e-sig that authorised the scaling.
- Change controlRequired when the requested scale falls outside the MMR's validated range.
V5 Ultimate ships with the Yield-Adjusted Batch Size controls already wired in — audit trail, e-signatures, validation evidence. Free trial, no credit card, onboard in days, not months.
